The rebuilding of a company from the ground up: Elan's grand plan Read the full story

Elan has completed life science deals with Theravance for royalties of previous GlaxoSmithKline deals in a $1 billion royalty financing deal. Read the full story

Johnson & Johnson biotech deals to sell shares in big biotech, Elan, for $11.25 per share as part of a $1 billion stock buyback plan. Read the full story

Elan, a leading biotech company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years Read the full story